Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Acquisition of Lideta Hälsovård
Mandate

Acquisition of Lideta Hälsovård

November 10, 2017 M&A

Vinge is advising Nordstjernan in conjunction with the acquisition of a majority of the shares in Lideta Hälsovård.

Lideta conducts primary care via 15 centres in Stockholm and in southern Sweden. The company has grown quickly since it was founded in 2001 by doctor Simon Larsson and currently has 93 000 listed patients, 350 employees and a turnover of approximately MSEK 500.

The transaction is conditional upon approval by the relevant competition authorities, which is expected during the fourth quarter of 2017.

Vinge’s team consisted of partners Johan Winnerblad and Kristina Ekberg, associates Samra Baytar, Johanna Wiberg and Marion Kronberg. Grant McKelvey and Xandra Ståhlberg provided competition law advice.

Related

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.
October 22, 2024

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its directed share issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.
October 22, 2024

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS

 Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission, have among other things involved restructuring, debt write-downs as well as an investment by a consortium consisting of Castlelake, Air France-KLM, Lind Invest and the Danish state. In total, the investment amounted to approximately USD 1.2 billion in SAS, divided into USD 475 million in unlisted equity and USD 725 million in convertible debt.
October 21, 2024